Abstract:Abstract Background Resistance to targeted therapies represents a significant hurdle to successfully treating hepatocellular carcinoma (HCC). While epigenetic abnormalities are critical determinants of HCC relapse and therapeutic resistance, the underlying mechanisms are poorly understood. We aimed to address whether and how dysregulated epigenetic regulators have regulatory and functional communications in establishing and maintaining drug resistance. Methods HCC-resistant cells were characterized by CCK-8, IncuCyte Live-Cell analysis, flow cytometry and wound-healing assays. Target expression was assessed by qPCR and Western blotting. Global and promoter DNA methylation was measured by dotblotting, methylated-DNA immunoprecipitation and enzymatic digestion. Protein interaction and promoter binding of DNMT3a-TET2 were investigated by co-immunoprecipitation, ChIP-qPCR. The regulatory and functional roles of DNMT3a and TET2 were studied by lentivirus infection and puromycin selection. The association of DNMT and TET expression with drug response and survival of HCC patients was assessed by public datasets, spearman correlation coefficients and online tools. Results We identified the coordination of DNMT3a and TET2 as an actionable mechanism of drug resistance in HCC. The faster growth and migration of resistant HCC cells were attributed to DNMT3a and TET2 upregulation followed by increased 5mC and 5hmC production. HCC patients with higher DNMT3a and TET2 had a shorter survival time with a less favorable response to sorafenib therapy than those with lower expression. Cancer stem cell-like cells (CSCs) displayed DNMT3a and TET2 overexpression, which were insensitive to sorafenib. Either genetic or pharmacological suppression of DNMT3a or/and TET2 impaired resistant cell growth and oncosphere formation, and restored sorafenib sensitivity. Mechanistically, DNMT3a did not establish a regulatory circuit with TET2, but formed a complex with TET2 and HDAC2. This complex bound the promoters of oncogenes (i.e., CDK1, CCNA2, RASEF), and upregulated them without involving promoter DNA methylation. In contrast, DNMT3a-TET2 crosstalk silences tumor suppressors (i.e., P15, SOCS2) through a corepressor complex with HDAC2 along with increased promoter DNA methylation. Conclusions We demonstrate that DNMT3a and TET2 act coordinately to regulate HCC cell fate in DNA methylation-dependent and -independent manners, representing strong predictors for drug resistance and poor prognosis, and thus are promising therapeutic targets for refractory HCC.

Transposable Elements-Mediated Recruitment of KDM1A Epigenetically Silences HNF4A Expression to Promote Hepatocellular Carcinoma

Retraction Note: Upregulation of Long Noncoding RNA ZEB1-AS1 Promotes Tumor Metastasis and Predicts Poor Prognosis in Hepatocellular Carcinoma

HN1L-mediated Transcriptional Axis AP-2γ/METTL13/TCF3-ZEB1 Drives Tumor Growth and Metastasis in Hepatocellular Carcinoma.

Role of ten-eleven translocation proteins and 5-hydroxymethylcytosine in hepatocellular carcinoma

3D‐epigenomic Regulation of Gene Transcription in Hepatocellular Carcinoma

Integrative bioinformatics and experimental analysis revealed TEAD as novel prognostic target for hepatocellular carcinoma and its roles in ferroptosis regulation

TEAD4 Induced Positive Feedback Activation of E2R/YAP1 Axis and Promoted Epithelial-mesenchymal Transition through Up-regulating TWIST1 Directly in HCC

Coordinated activation of DNMT3a and TET2 in cancer stem cell-like cells initiates and sustains drug resistance in hepatocellular carcinoma

Integrative Analysis of Epigenome and Transcriptome Data Reveals Aberrantly Methylated Promoters and Enhancers in Hepatocellular Carcinoma

Identification of Potential Transcription Factors, Long Noncoding RNAs, and Micrornas Associated with Hepatocellular Carcinoma

Epigenetic silencing of miR-144/451a cluster contributes to HCC progression via paracrine HGF/MIF-mediated TAM remodeling

ZNF740 facilitates the malignant progression of hepatocellular carcinoma via the METTL3/HIF‑1A signaling axis

Double-negative Feedback Loop Between Wnt/β-catenin Signaling and HNF4α Regulates Epithelial-Mesenchymal Transition in Hepatocellular Carcinoma

Integrative Epigenetic Analysis Reveals AP-1 Promotes Activation of Tumor-Infiltrating Regulatory T Cells in HCC

Epigenetic regulation of HBV-specific tumor infiltrating T cells in HBV-related HCC

Loss of Tumor Suppressor IGFBP4 Drives Epigenetic Reprogramming in Hepatic Carcinogenesis.

TATA-box-binding Protein Promotes Hepatocellular Carcinoma Metastasis Through Epithelial-Mesenchymal Transition.

Crosstalk Between Macrophage-Derived PGE2 and Tumor UHRF1 Drives Hepatocellular Carcinoma Progression.

Transcriptional Silencing of the TMS1/ASC Tumour Suppressor Gene by an Epigenetic Mechanism in Hepatocellular Carcinoma Cells

Key Signaling Pathways, Genes and Transcription Factors Associated with Hepatocellular Carcinoma

The Mechanism Underlying the ncRNA Dysregulation Pattern in Hepatocellular Carcinoma and Its Tumor Microenvironment